CRO will use Veeva Vault EDC to deliver a better
experience to patients, research sites, and sponsors
PLEASANTON, Calif., June 19,
2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV)
today announced that Vita Global Sciences is partnering with Veeva
to modernize its clinical data management processes and improve
collaboration with key trial stakeholders. With Veeva Vault EDC,
the CRO is establishing a foundation for study efficiency and
faster study builds.
"Veeva Vault EDC allows us to simplify our processes while
ensuring a seamless experience for patients, research sites, and
sponsors," said Kelly Forester,
director of clinical data management at Vita Global Sciences.
"Partnering with Veeva advances our mission to deliver innovations
that can profoundly impact patient lives."
The CRO will use Vault EDC to design and deliver complex studies
for its sponsor clients. Looking ahead, Vita Global Sciences plans
to add Veeva Clinical Database (CDB) to aggregate and clean data
from all sources, and Veeva RTSM to randomize patients and optimize
trial supply management. This ensures Vita Global Sciences can run
the study clients want while gaining visibility and control of
trial data. With modern clinical data management applications on a
single platform, the company can reduce manual processes for
improved accuracy and speed.
"Veeva Vault EDC will help advance Vita Global Sciences
processes as they move toward the future of clinical trials," said
Jon Young, director, Veeva Vault
Clinical Data Management strategy. "By establishing a clinical data
foundation, Vita Global Sciences can accelerate study builds and
manage changes with no downtime for faster trials that can improve
patient outcomes."
Vault EDC is part of Veeva Vault Clinical Data Management,
bringing together EDC and Veeva CDB for next-generation
clinical data management. To learn more, visit
veeva.com/VaultClinicalDataManagement.
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's
products and services and the expected results or benefits from use
of our products and services. These statements are based on our
current expectations. Actual results could differ materially from
those provided in this release and we have no obligation to update
such statements. There are numerous risks that have the potential
to negatively impact our results, including the risks and
uncertainties disclosed in our filing on Form 10-Q for the period
ended April 30, 2024, which you can
find here (a summary of risks which may impact our
business can be found on pages 35 and 36), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
|
|
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/vita-global-sciences-partners-with-veeva-to-streamline-clinical-data-management-302175454.html
SOURCE Veeva Systems